350 results about "Polycyclic compound" patented technology

Provided are a polycyclic compound of a compound having such a structure that two benzene rings bond to a central benzene ring each other to form a fused ring and another fused ring bonds to a terminal thereof, and an organic electroluminescence device including one or more organic thin film layers containing a light emitting layer between a cathode and an anode, in which at least one of the organic thin film layers includes the polycyclic compound of the present invention. The organic electroluminescence device has high luminous efficiency, no defect in pixels, and long lifetime. In addition, provided is a polycyclic compound realizing the organic electroluminescence device.

The present invention provides a stable new condensed polycyclic compound which is not likely to form a molecular association. In addition, the present invention also provides an organic light-emitting element having a high light-emitting efficiency and a low drive voltage. In the condensed polycyclic compound in Claim 1 represented by the general formula [1], R1, R2 and R5 are each independently selected from a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, an aryl group, and a heterocyclic group. R3 and R4 each represent an alkyl group having 1 to 4 carbon atoms. The aryl group and the heterocyclic group each may have at least one of an alkyl group, an aralkyl group, an aryl group, a heterocyclic group, an amino group, and an alkoxy group as a substituent.

By providing a novel polycyclic aromatic compound in which a plurality of aromatic rings are linked via a boron atom, a nitrogen atom, or the like, options of a material for an organic EL element are increased. In addition, by using the novel polycyclic aromatic compound as a material for an organic electroluminescent element, an excellent organic EL element is provided.

The present invention addresses the problem of providing a novel polycyclic aromatic compound and an organic electroluminescent element using the same. The above problem is solved by providing a novel polycyclic aromatic compound in which a plurality of aromatic rings are connected by boron atoms, oxygen atoms, or the like, thereby increasing the number of options for organic EL element materials, and also solved by providing a superior organic EL element using said novel polycyclic aromatic compound as an organic EL element material.

New anionic surfactants and methods of preparation which are derived from aromatic or substituted aromatic molecules and alkenesulfonic acid. Wherein the aryl compound is alkylated and sulfonated in one-step with an alkene sulfonic acid prior to sulfonic acid neutralization. The methods allow the functional sulfonate group to be attached to the end of the alkyl chain rather than to the aromatic ring thus allowing for selective substituted groups, either branched, linear or alkoxylated or combinations thereof to be placed on the aryl compound prior to sulfonation and alkylation. The invention uses the alkene sulfonic acid produced from thin-film sulfonation of an alpha-olefin to alkylate benzene, mono-substituted aromatic, poly-substituted aromatic, alkylbenzene, alkoxylated benzene, polycyclic aromatic, mono-substituted polycyclic aromatic, poly-substituted polycyclic aromatic, naphthalene, alkylnaphthalene, phenol, alkylphenol, alkoxylated phenol, and alkoxylated alkylphenolalkyl substituted or polysubstituted cyclic or polycyclic compounds to produce the corresponding sulfonic acid having an additional alkyl group derived from the alpha-olefin used during the thin-film sulfonation which is either linear or branched.

PCT No. PCT / JP96 / 03300 Sec. 371 Date Jul. 10, 1997 Sec. 102(e) Date Jul. 10, 1997 PCT Filed Nov. 11, 1996 PCT Pub. No. WO97 / 17415 PCT Pub. Date May 15, 1997The present invention provides a guest-host liquid-crystal composition comprising a host liquid-crystal composition containing one or more dichroic dyes, characterized in that the host liquid-crystal composition comprises as the main component a polycyclic compound having three or more rings and having no cyano group in the direction of the molecular axis, the proportion of the polycyclic compound component having three or more rings in the host liquid-crystal composition being 75% by mole or higher, and that the guest-host liquid-crystal composition has an order parameter (S value) of 0.76 or higher. The invention further provides a liquid-crystal display element employing the composition. This guest-host liquid-crystal composition shows excellent dichroism or a high order parameter.

A compound represented by the formula (I):or a pharmacologically acceptable salt thereof, wherein Ar1 represents an imidazolyl group or the like which may be substituted with a C1-6 alkyl group, Ar2 represents a phenyl group or the like which may be substituted with a C1-6 alkoxy group, X1 represents a double bond or the like and Het represents a triazolyl group or the like which may be substituted with a C1-6 alkyl group or the like, is effective as a therapeutic or prophylactic agent for a disease caused by Aβ.

A photopolymerization initiator comprising (A) a photo acid-generating compound such as diaryliodonium salt (e.g., diphenyl iodonium, bis(p-chlorophenyl)iodonium, etc.), (B) a photo oxidation radical-generating compound such as diarylketone compound, alpha-diketone compound or ketocoumarin compound, and (C) a fused polycyclic aromatic compound such as 1,4-dimethylnaphthalene, 1-methylanthracene, 9-methylanthracene, 9,10-dimethylanthracene or 9,10-diethylanthracene. The photopolymerization initiator makes it possible to efficiently polymerize the cationically polymerizable monomer by the irradiation with visible light.

In one embodiment of the present invention, a novel fused polycyclic aromatic compound of the present invention is (a) a compound including a benzodichalcogenophenobenzodichalcogenophene (BXBX) skeleton further having an aromatic ring(s) located outside the BXBX skeleton, or (b) a compound including a BXBX skeleton in which a benzene ring is substituted with a heterocyclic ring. The compound can strengthen intermolecular interaction due to greater π electron orbits. This improves an electron field effect mobility of an organic semiconductor device that is manufactured by use of the compound as an organic semiconductor material. Further, since the number of fused rings included in the compound is small, the compound does not cause problems that generally occur in compounds having an extremely large number of fused rings, i.e., poor solubility in solvent and poor atmospheric stability due to high affinity to oxygen. As a result, the fused polycyclic aromatic compound of the present invention can be preferably used as an organic semiconductor material.

Disclosed is a polycyclic compound having a structure wherein two benzene rings are so bonded to a central benzene ring as to form a condensed ring to an end of which another condensed ring is bonded. Also disclosed is an organic electroluminescent device having one or more organic thin film layers including a light-emitting layer between a cathode and an anode, wherein at least one of the organic thin film layers contains the polycyclic compound. The organic electroluminescent device has high luminous efficiency, no pixel defects, and long life. The polycyclic compound enables realization of such an organic electroluminescent device.

The present invention relates to a method for the preparation of a layer of a plasma-polymerised material on the surface of a substrate, e.g. a substrate of a glass, an organosiloxane-based or polysiloxane-based material, silicon, fluoro-polymer (e.g. Teflon®), etc. The present invention also relates to novel objects and microstructured or micro-patterned devices, e.g. by lift-off techniques, in particular such objects and devices that have layers of electrically conducting materials providing a conductivity of at least 0.01 S / cm. A feature of the invention is the plasma-polymerization of a compound including at least one polycyclic compound, said polycyclic compound(s) comprising a non-aromatic heterocyclic ring fused to an aromatic or heteroaromatic ring or ring system. Examples of such compounds are 3,4-ethylenedioxythiophene (EDT) forming layers of poly(ethylenedioxythiophene) (PEDT), and piperonylamine, piperonyloyl chloride, safrole, 3,4-ethylenedioxypyrrole, 3,4-ethylenedioxy-N-methylpyrrole, and 3,4-methylenedioxythiophene.

The present invention relates to chemical compounds having a general formula Iwherein A, B, C1, C2, D, L1, L2 and R3-4 are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Tie-2 and Aurora kinase enzymes thereby influencing angiogenesis and the process of cell cycle and cell proliferation, respectively, to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of various protein kinases.

A new condensed polycyclic compound represented by general formula [I]: wherein R1 is hydrogen, halogen, cyano, a substituted amino or a group selected from the group consisting of alkyl, aralkyl, aryl, heterocyclic, each having no substituent or a substituent; and Ar1 to Ar5 are the same or different and are each independently a condensed polycyclic aromatic group or a condensed polycyclic heterocyclic group, each having no substituent or a substituent is used for an organic light-emitting device that is extremely efficient in a light output with high luminance and is extremely durable.

A pharmaceutically active agent, a pharmaceutically active agent carrier and method of use thereof are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups, and at least two pharmaceutically active agents may be associated with the bridged polycyclic compound. In some embodiments, a bridged polycyclic compound may be pharmaceutically active. In some embodiments, a bridged polycyclic compound may be function as a carrier for pharmaceutically active agents.

The present invention provides a composition for forming a liquid crystal alignment film, which comprises a photoreactive polymer including a multicyclic compound having a photoreactive group on a main chain thereof. The present invention also provides a liquid crystal alignment film produced using the composition, and a liquid crystal display including the liquid crystal alignment film. The photoreactive polymer including the multicyclic compound on the main chain thereof has a high glass transition temperature, thus thermal stability is excellent. Since lattice vacancy is relatively large, the photoreactive group is capable of moving relatively freely in the main chain of the polymer, thus it is possible to improve a slow photoreaction rate, which is considered a disadvantage of a conventional polymer material.

An electrically conducting organic compound comprising a condensed polycyclic aromatic compound containing from 8 to 14 condensed rings and being solubilized in a solvent by the introduction of a functional group into any condensed ring of the compound. The electrically conducting organic compound is used as a constituent element in the production of electronic devices.

A pharmaceutically active agent, a pharmaceutically active agent carrier and method of use thereof are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups, and at least two pharmaceutically active agents may be associated with the bridged polycyclic compound. In some embodiments, one or more bridged polycyclic compounds may be applied to an oral surface of a human such that an oral malady may be inhibited and / or ameliorated.

Disclosed is a polycyclic compound having a p-conjugated heteroacene skeleton crosslinked via a carbon atom, a nitrogen atom, an oxygen atom or a sulfur atom. Also disclosed is a halogen compound which can be used for the synthesis of the polycyclic compound. Further disclosed is an organic electroluminescence element which comprises a cathode, an anode, and at least one organic thin film layer containing a light-emitting layer and arranged between the cathode and the anode, wherein at least one layer in the organic thin film layer comprises a material for the organic electroluminescence element. The organic electroluminescence element has high luminous efficiency and has long service-life. The polycyclic compound can be used for the production of the organic electroluminescence element. The halogen compound is an intermediate for the polycyclic compound.

The invention provides a polycyclic pyridone compound as well as pharmaceutical composition and an application thereof. Specifically, the polycyclic pyridone compound is a compound shown as the formula (I) or pharmaceutically acceptable salt, solvate or hydrate of the compound. The compound can be used for preparing drugs for preventing or treating infectious diseases of mammals, and is particularly used for preparing drugs for preventing, treating, relieving and / or treating orthomyxovirus infection such as influenza A virus, influenza B virus and influenza C virus.

The invention relates to a new compound and an organic electroluminescent device containing the compound. The structural formula of the compound is shown as below, Ar1 and Ar2 are respectively and independently selected from substituted or unsubstituted aromatic group, aromatic ethylene group, polycyclic aromatic group, polycyclic aromatic ethylene group, aromatic amine group and a polycyclic compound containing nitrogen atoms or a heterocyclic compound containing nitrogen atoms. The invention resolves the problems existing in the colorimetric purity, luminescent efficiency, etc. of the currently used luminescent materials. The material of the invention can be used as a luminescent material, and the electroluminescent device prepared of the material of the invention has the predominant performances of high colorimetric purity, high brightness and high efficiency.

The invention provides a deuterium-substituted polycyclic pyridone compound, a prodrug thereof, a composition containing the compound and application of the composition. The deuterium-substituted polycyclic pyridone compound is the compound shown in the formula (I) or a tautomer, stereoisomer, prodrug, crystalline form, pharmaceutically acceptable salt, hydrate or solvent compound thereof. The compound and the composition show the cap-dependent endonuclease inhibitory activity and have superior pharmacokinetic properties.

A pharmaceutically active agent, a pharmaceutically active agent carrier and method of use thereof are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups, and at least two pharmaceutically active agents may be associated with the bridged polycyclic compound. In some embodiments, one or more bridged polycyclic compounds may be applied to an topical surface and / or an otic surface of an animal (e.g., canine, feline) such that an topical malady and / or otic malady may be inhibited and / or ameliorated.

Disclosed is an organic electroluminescent device (organic EL device) that is improved in luminous efficiency, sufficiently secures driving stability, and has a simple configuration. This organic EL device has a light-emitting layer between an anode and a cathode piled one upon another on a substrate and the said light-emitting layer contains a fused polycyclic compound in which seven or more rings are fused together as a host material. The aforementioned fused polycyclic compound has a structure formed by fusing two or more indole rings to a carbazole ring. A specific example thereof is the compound represented by the following formula.